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Background: There is a close relationship between cardiovascular disease and cardiac energy metabolism, and we
have previously demonstrated that palmitate inhibits myocyte contraction by increasing Kv channel activity and
decreasing the action potential duration. Glucose and long chain fatty acids are the major fuel sources supporting
cardiac function; however, cardiac myocytes can utilize a variety of substrates for energy generation, and previous
studies demonstrate the acetate is rapidly taken up and oxidized by the heart. In this study, we tested the effects of
acetate on contractile function of isolated mouse ventricular myocytes.
Results: Acute exposure of myocytes to 10 mM sodium acetate caused a marked, but transient, decrease in systolic
sarcomere shortening (1.49 ± 0.20% vs. 5.58 ± 0.49% in control), accompanied by a significant increase in diastolic
sarcomere length (1.81 ± 0.01 μm vs. 1.77 ± 0.01 μm in control), with a near linear dose response in the 1–10 mM
range. Unlike palmitate, acetate caused no change in action potential duration; however, acetate markedly
increased mitochondrial Ca2+ uptake. Moreover, pretreatment of cells with the mitochondrial Ca2+ uptake blocker,
Ru-360 (10 μM), markedly suppressed the effect of acetate on contraction.
Conclusions: Lehninger and others have previously demonstrated that the anions of weak aliphatic acids such as
acetate stimulate Ca2+ uptake in isolated mitochondria. Here we show that this effect of acetate appears to extend
to isolated cardiac myocytes where it transiently modulates cell contraction.Background
It is well established that the cardiac myocardium is cap-
able of oxidizing a variety of carbon sources to supply
the energy required for continuous contraction. Lipids,
carbohydrates, ketone bodies, and amino acids can all
support some degree of ATP synthesis in the heart. The
loss of metabolic flexibility in the diseased heart may
lead to abnormal contractile function. For example, we
recently demonstrated that mice overexpressing fatty acid
transport protein (FATP4) in the heart have impaired dia-
stolic function [1]. Similarly, acute exposure to long chain
fatty acids has been shown to cause a decrease in cardio-
myocyte contractility through effects on increases in volt-
age gated K+ currents thus causing shortening of the
action potential [2].* Correspondence: Thomas.Flagg@usuhs.edu
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unless otherwise stated.In a continued effort to understand the relationship of
cardiac metabolism and cell function, we set out to test
the effects of acetate on contraction. Several studies have
examined the effect of acetate on cardiac contraction
with equivocal results. In isolated cells, acetate tends to
increase cell shortening after 10 minutes of exposure [3].
In isolated papillary muscle and in vivo, sodium acetate
has been shown to reduce contractility [4,5], whereas
other studies suggest that acetate causes an increase in
contractility [6]. The effects of acetate on cardiovascular
function in vivo are complicated by the concomitant
vasodilatory effects that also must be considered [6].
These mixed results are consistent with the idea that
acetate can affect cardiac contractility, but the cellular
mechanisms remain poorly understood.
Although it is typically found in low concentrations
(~0.2 mM) in non-ruminant mammals [7], acetate oxi-
dation can account for ~10% of the total CO2 output in
humans [8]. Acetate can be converted to acetyl CoA by
acetyl CoA sythetase (AceCS2) in the mitochondrial
matrix [9] and the resultant acetyl CoA can then enteral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in that the expression of the mitochondrial AceCS2 is
higher than in any other tissue, so the heart is ideally
suited to use acetate as a fuel source [9]. Metabolic studies
by Randle demonstrate that acetate is rapidly oxidized in
the myocardium [10]. In some isolated heart studies, acet-
ate combustion can account for ~90% of total respiration
to the exclusion of glucose oxidation [11], although others
suggest that at physiological workloads both acetate and
glucose are effectively utilized [12]. Acetate can also affect
isolated mitochondria independent of its oxidation, where
Lehninger and others have demonstrated that exposure to
acetate causes a rapid increase in mitochondrial matrix
Ca2+ and osmotic swelling [13-15].
In this context, we investigated the effects of acetate
on cardiac contractility in isolated cardiac myocytes. We
tested the effects of acetate throughout a 10 minute
exposure. The results demonstrate that acetate inhibits
systolic function and increases cell relaxation within 2 mi-
nutes of exposure. The decrease in systolic function is
transient, however, and contraction amplitude is restored
within 10 minutes. These effects are independent of
changes in action potential duration; however, the effects
of acetate were inhibited by blockade of mitochondrial
Ca2+ uptake with Ru-360, indicating that acetate causes




All animals used in this study were male, aged 2–4
months, C57Bl6/J. All procedures complied with the stan-
dards for the care and use of animal subjects as stated in
the Guide for the Care and Use of Laboratory Animals
(NIH publication No. 85–23, revised 1996). Protocols
were approved by the USUHS Institutional Animal Care
and Use Committee.
Solutions (concentrations in mM)
Normal Tyrode Soution (NT): NaCl, 137; KCl, 5.4; NaH2PO4,
0.16; glucose, 10; MgCl2, 0.5; CaCl2, 1.8; HEPES, 5.0;
NaHCO3, 3.0; pH 7.35 - 7.4.
Wittenberg Isolation Medium (WIM): NaCl, 116; KCl,
5.3; NaH2PO4, 1.2; glucose, 11.6; MgCl2, 3.7; HEPES, 20;
L-glutamine, 2.0; NaHCO3, 4.4; KH2PO4, 1.5; 1X essential
vitamins; 1X amino acids; pH 7.3-7.4.
Myocyte isolation
Isolation of ventricular myocytes was performed as de-
scribed previously [1,2,16]. Briefly, mice were anesthetized
by intra-peritoneal injection with 2,2,2 tribromoethanol
(250 mg/kg). Following cervical dislocation, the heart was
rapidly excised and the aorta cannulated. The heart was
retrogradely perfused with Ca2+-free WIM solution for5 minutes followed by perfusion with a digestion so-
lution containing 100 μM CaCl2 and 1 mg/mL collage-
nase (Type 2, Worthington Biochemical). Left ventricular
cells were gently dispersed by manual trituration using a
pasteur pipette in WIM solution supplemented with
bovine serum albumin (1 mg/mL) and 500 μM CaCl2.
Cells were washed twice with WIM solution and twice
with HEPES-buffered M199 solution and stored at
room temperature. Cells were used for experiments within
12 hours of isolation in all cases.
Myocyte contraction measurements
Unloaded sarcomere shortening was measured in freshly
isolated ventricular myocytes, as described previously
[1,2]. Briefly, isolated myocytes were transferred into a
recording chamber mounted on an Olympus X51
inverted microscope and superfused with normal Tyrode
solution saturated with room air. Additions to the Tyrode
solution are described in the text. The mitochondrial cal-
cium uptake inhibitor, Ru-360, was obtained from EMD
Biosciences; all other chemicals were purchased from
Sigma. Typically, cells were field stimulated to contract at
1 Hz. When thapsigargin was applied to cells, the stimula-
tion frequency was reduced to 0.5 Hz. Video images were
acquired using a Myocam camera and IonWizard software
(IonOptix, Inc.). All experiments were performed at room
temperature.
Mitochondrial Ca2+ measurements
Freshly isolated ventricular myocytes were plated on
laminin-coated (100 μg/mL) Mat-Tek dishes for fluores-
cence imaging. Cells were loaded with Rhod-2-AM (5 μM)
for 30 minutes in normal Tyrode solution containing pro-
benecid (500 μM) to inhibit dye export and 200 μMMnCl2
to quench cytoplasmic fluorescence as has been previously
reported [17,18]. After loading, cells were washed twice
with normal Tyrode solution supplemented with probene-
cid and 200 μM MnCl2 and transferred to the microscope
stage. Cell images were obtained every 10 seconds for
10 minutes. Data were plotted as background-subtracted
Rhod-2-AM fluorescence normalized to mean signal dur-
ing the first 6 images recorded prior to addition of acetate.
Action potential measurements
Action potentials were measured in freshly isolated ven-
tricular myocytes using whole cell current clamp. Briefly,
following acquisition of the whole cell mode, cell holding
potential was adjusted to −70 mV using current injection.
Action potentials were evoked by suprathreshold stimuli
(2 nA, 3 msec) delivered at 1 Hz. Action potentials were
recorded continuously during 5 minute exposure to acetate
followed by 5 minutes washout. Average traces constructed
from 25 consecutive action potentials during control, acet-
ate exposure (2 minutes) and washout (5 minutes) were
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mined at 90% repolarization and referenced to the peak of
the action potential.
Data analysis
All data were analyzed using ClampFit, IonWizard, ImageJ
and Microsoft Excel software and (except where noted)
results are presented as mean ± SEM (standard error of
the mean). Statistical analysis was performed with built-in
functions of Excel or with the Sigma XL software add-in.
Statistical tests and p-values are denoted in the figure le-
gend and text where appropriate.
Results
Acute exposure to acetate transiently impairs cardiac
contraction and increases diastolic sarcomere length
To test whether the short chain fatty acid, acetate, exerts
negative inotropic effects, we continuously monitored aver-
age sarcomere length in isolated mouse cardiomyocytes
acutely exposed to Tyrode solution containing 10 mM so-
dium acetate. Three major consequences of acetate expos-
ure were observed. Figure 1 shows that acetate caused a
transient decrease in active sarcomere shortening. At two
minutes following acetate application, fractional shortening
was markedly decreased from 5.6 ± 0.5 to 1.5 ± 0.2 (n = 12,
p < 0.001, paired t-test). In the continued presence of
acetate, contraction amplitude gradually recovered and
returned to baseline after approximately 10 minutes. We
also noted a marked increase in fractional sarcomere short-















































Figure 1 Acetate causes a transient decrease of fractional sarcomere sh
mouse cardiac myocytes. (A) Representative recording of average sarcomer
normal Tyrode solution (NT) supplemented with 10 mM sodium acetate. Sum
acetate on (B) fractional sarcomere shortening and (C) diastolic sarcomere lenIn addition, exposure to acetate significantly increased the
diastolic sarcomere length. We next examined the con-
centration dependence of the decrease in contraction ob-
served at two minutes and diastolic sarcomere length
following the exposure to acetate. Figure 2 shows that
the negative inotropic effect of acetate is concentration
dependent. Data were fit with a modified Hill equation
with an IC50 = 5.6 mM and Hill coefficient of 1.4. There
was no apparent concentration dependence for the effect
on diastolic sarcomere length.
Acetate exposure does not affect the action potential
duration
We previously demonstrated that acute exposure to long
chain fatty acids shortens the action potential duration
principally by increasing outward voltage-dependent K+
currents encoded by Kv2.1 and Kv1.5, with no effect
on IK1 [2]. Considering that short-chain fatty acids
might have similar effects on cell excitability, we exam-
ined the effect of acetate on the action potential duration
(APD90) (Figure 3). In contrast to results with palmitate,
APD90 (24.5 ± 3.2 msec in control) was unaffected by acet-
ate (25.0 ± 3.5 msec, p >0.05, paired t-test), suggesting that
a different molecular mechanism underlies the inotropic
effects of acetate.
Acetate exposure stimulates mitochondrial Ca2+ uptake
It has been shown previously that acetate increases Ca2+
uptake in isolated liver and heart mitochondria [13-15].
In this light, we hypothesized that the acute application1.7
1.8
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Figure 2 Concentration-dependence of acetate effect on fractional shortening and diastolic sarcomere length. (A) Single averaged
contractions acquired in experiments as described in Figure 1 at different concentrations of sodium acetate. Contractions in normal Tyrode
(Control, dotted line) and at 2 minutes following exposure to acetate solution (Acetate, solid line) are shown. 10 mM NaCl, instead of
sodium acetate, was added to normal Tyrode to collect the zero acetate data. (B) Acetate concentration response curve for maximum
contraction inhibition. Data were fit with a modified Hill equation (solid line): FS/FS0 = 1/(1 + ([Acetate]/IC50)
h), where IC50 is the half-maximal
inhibitory concentration of acetate (IC50 = 5.6 mM) and h is the Hill coefficient (h = 1.3). (C) There was no apparent acetate concentration dependence









































Figure 3 Acetate does not affect the action potential duration (APD90). (A) Representative action potentials recorded before (Control, gray
line) and 2 minutes following acetate exposure (Acetate, black line). Action potentials were recorded in whole cell current clamp mode and were
evoked suprathreshold current injections. Records are averaged traces from 25 consecutive action potentials. (B) Summary APD90 data from all
(n = 7) experiments as in A. Acetate exposure did not affect the APD90 (24.5 ± 3.2 msec in acetate vs. 25.0 ± 3.5 msec in control).
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Ca2+ uptake, leaving less Ca2+ available to activate the
myofilaments. To test this hypothesis, we first monitored
mitochondrial Ca2+ during exposure to acetate using the
fluorescent Ca2+ indicator, Rhod-2 AM (5 μM) in the
presence of 200 μM MnCl2 to quench cytosolic fluores-
cence [17,18]. Figure 4 shows normalized cell fluores-
cence during exposure to 10 mM acetate in the presence
or absence of the mitochondrial Ca2+ uptake inhibitor,
Ru-360 (n = 9 and 8 respectively). This concentration of
Ru-360 was chosen as it has previously been shown to
have no effect on transmembrane Ca2+ fluxes other than
mitochondrial uptake [19,20]. The results indicate that
acetate causes a specific increase in Rhod-2 fluorescence
consistent with the conclusion that acetate increases
mitochondrial Ca2+ uptake.
Inhibition of mitochondrial Ca2+ uptake attenuates the
effects of acetate on fractional shortening and diastolic
sarcomere length
If the acetate-dependent increase in mitochondrial Ca2+
is responsible for the reduction of myocyte fractional
shortening, we reasoned that inhibiting mitochondrial
Ca2+ uptake would reduce or abolish the effect of acetate
on myocyte contraction. To test this hypothesis, we in-
cubated cells for 30 minutes with 10 μM Ru-360, and
then measured the effects of acetate on sarcomere short-
ening. Figure 5 shows that Ru-360 treatment significantly
attenuated the effect of acetate on both diastolic sarco-
mere length and fractional sarcomere shortening. Interest-
ingly, pretreatment with Ru-360 alone also had a marked
effect on contractile function prior to acetate exposure. As
shown in Figure 5B (inset), fractional sarcomere shorten-

























Figure 4 Acetate stimulates mitochondrial Ca2+ uptake. Summary of rh
acetate in the presence (n = 8) or absence (n = 10) of Ru-360 (10 μM). Back
during the period prior to addition of 10 mM acetate (n =10) or control (n13.03 ± 1.17% in cells pretreated with Ru-360 compared
with 5.83 ± 0.43% in control cells not exposed to Ru-360.
Taken together, these data support the conclusion that
acetate stimulates mitochondrial Ca2+ uptake, leading to
reduced availability of Ca2+ for myofilament activation.
Partial inhibition of SERCA inhibits recovery of systolic
function during acetate application
The acetate-induced stimulation of mitochondrial Ca2+
uptake appears to be the seminal event leading to re-
duced inotropy. However, in the sustained presence of
acetate, fractional shortening recovers to control levels
by 10 minutes. This suggests that during the early phase
of acetate exposure, cytosolic Ca2+ released from the SR
bypasses the myofilaments and enters the mitochondria.
We hypothesized that the recovery of contraction during
the latter phase of acetate exposure reflects refilling of
the SR to replace the Ca2+ lost to the mitochondria. Pre-
vious studies have utilized brief application of 1 μM
thapsigargin to partially inhibit SERCA activity [21]. We
therefore treated cells with 1 μM thapsigargin for 2–5
minutes prior to transfer to the bath for recording. No
thapsigargin was added to the recording solutions. As
expected, cell relaxation was markedly slowed by SERCA
inhibition and therefore cells were stimulated at 0.5 Hz
(instead of 1 Hz) for these experiments (Figure 6). Thap-
sigargin pretreatment markedly inhibited fractional
shortening as expected (Figure 6B, inset), but exposure
to acetate still resulted in a decrease in contraction
amplitude and increase in diastolic sarcomere length simi-
lar to control, untreated cells. It should be noted, how-
ever, that the recovery of contraction typically observed
during the latter phase of acetate application as well as
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Figure 5 Inhibition of mitochondrial Ca2+ uptake with Ru-360 inhibits the effects of acetate on cell contraction. (A) Representative
recording of average sarcomere length assessed continuously throughout application and removal of normal Tyrode solution (NT) supplemented
with 10 mM sodium acetate in cells pretreated with 10 μM Ru-360 for 30–60 minutes and maintained in Ru-360 throughout the acetate exposure.
Summary data from experiments as in A (n = 11) illustrate that pretreatment with Ru-360 markedly suppresses the effect of acetate on both
(B) fractional shortening and (C) diastolic sarcomere length.
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exposed to thapsigargin prior to acetate. This finding sug-
gests that the recovery of contraction during acetate treat-
ment reflects refilling of the sarcomplasmic reticulum
with Ca2+.Discussion
Acetate and cardiac function
There have been previous studies that have examined
the effects of acetate on cardiovascular function and en-
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Figure 6 Thapsigargin pretreatment specifically impairs the recovery of contraction during acetate exposure. (A) Representative
recording of average sarcomere length assessed continuously throughout application and removal of normal Tyrode solution (NT) supplemented
with 10 mM sodium acetate in cells pretreated with thapsigargin (1 μM) for 2–5 minutes. As expected, cell relaxation was markedly slowed so
contractions were evoked at 0.5 Hz. (B & C) Summary data from experiments as in A (n = 9). Thapsigargin pretreatment had no effect on the
acetate induced decrease in fractional shortening or increase in diastolic sarcomere length, but markedly blunted the recovery of contraction
typically observed from 2–10 minutes during acetate application.
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tive inotropic effects which appear to be transient [4,5].
It should also be noted that acetate infusion can also
cause an acute reduction of the blood pressure that is
most likely dependent on the increase in AMP associ-
ated with the conversion of acetate to acetyl CoA andlocal release of the vasodilator adenosine [6], complicat-
ing the interpretation of experiments in vivo. Neverthe-
less, the data in the present study indicate that acetate
exerts effects on cardiac contraction by directly modu-
lating myocyte function, at least partially independent of
energy metabolism.
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contractile function
The present data provide evidence for a calcium-dependent
mechanism linking acetate exposure with contractile func-
tion. Unlike the long chain fatty acid palmitate [2], the
short chain fatty acid acetate caused no marked change in
APD. Instead, we provide evidence that acetate caused a
marked increased in mitochondrial Ca2+ accumulation.
Moreover, the effect of acetate was markedly attenuated
by pretreatment of myocytes with Ru-360, an inhibitor of
mitochondrial Ca2+ uptake. Ru-360 is commonly used to
inhibit mitochondrial Ca2+ uptake in a number of studies
due to its ability to permeate cell membranes and it has
been previously shown to have little if any effect on other
transmembrane Ca2+ transport processes, including SR
Ca2+ uptake and release, L-type Ca2+ channel and sodium
calcium exchange function [19]. Our data is consistent
with the conclusion that acetate uptake is coupled with an
increase in mitochondrial Ca2+ and that this decreases, at
least transiently, the amount of Ca2+ available for contrac-
tion of unloaded cardiomyocytes.
Interestingly, the effects of acetate on cell contraction
were transient, with complete recovery of fractional short-
ening within 10 minutes of continuous exposure. This
result could imply that as Ca2+ is sequestered in the mito-
chondria in the presence of acetate, additional Ca2+ enters
the cell and refills the SR Ca2+ stores. We found that the
acute decrease in contraction amplitude and increase in
diastolic sarcomere length were unaffected by pretreatment
with thapsigargin to attenuate SERCA activity. Interestingly,
however, the recovery of depressed myocyte contractility
during sustained acetate exposure and the abrupt increase
in contraction amplitude due to acetate removal were no
longer observed when cells were pretreated with thapsi-
gargin. One possible explanation of this phenomenon is
that inhibition of SR Ca2+ store replenishment prevents
the restoration of fractional shortening.
Acetate effects on mitochondria
Mitochondrial uptake of acetate has been shown to be
coupled with increases in Ca2+ uptake and swelling [13]. It
was proposed that direct transport of phosphate or anions
of weak acids like acetate can permeate the mitochondrial
membrane generatings a driving force for Ca2+ uptake
into the mitochondrial matrix. Similar observations dem-
onstrate that acetate or phosphate increase the rate of
mitochondrial Ca2+ uptake in a concentration dependent
manner [14] and that acetate increases mitochondrial
Ca2+ uptake in heart mitochondria [15]. The data in the
present study do not delineate the molecular transporters
mediating Ca2+ entry into the mitochondria. In addition
to the mitochondrial Ca2+ uniporter [22], the mitochon-
drial ryanodine receptor (mRyr) [23], or Ca2+/H+ exchan-
ger (Letm1) [24] could play a role in the acetate-inducedincrease in mitochondrial Ca2+. Nevertheless, here we
present pharmacological evidence showing that acetate is
apparently coupled with an increase in mitochondrial
Ca2+ in isolated cardiac myocytes and it is plausible to as-
sume that this decreases the amount of Ca2+ available for
contraction.
In isolated mitochondria, acetate also caused osmotic
swelling [13]. Given the tight interfibrillar packing of
mitochondria in the heart [25,26], acetate associated mito-
chondrial swelling might also be linked to the observed in-
crease in diastolic sarcomere length. Interestingly, the
effect of acetate on diastolic sarcomere length, unlike the
effect on contraction, is sustained throughout acetate ex-
posure and shows little concentration dependence. This
observation is consistent with the conclusion that acetate
causes the mitochondria to swell increasing the sarcomere
spacing. While active cell shortening recovers as the SR
refills with Ca2+, the mitochondria remain swollen and the
increased diastolic sarcomere length is maintained. Given
the structural constraints, it seems possible that swelling
is physically limited possibly explaining the absence of a
clear concentration dependence.
The observed delay from acetate application to initial
effects on contraction is similar to the time course for
conversion of acetate to acetyl CoA observed by Randle
[10]. Acetate has been shown to decrease the phosphor-
ylation potential [27] resulting in decreased free energy
from ATP hydrolysis; since the demand likely remains
constant, the cell must increase the rate of respiration to
cover the difference. This might suggest that acetate oxi-
dation increases mitochondrial respiration with concomi-
tant increases in mitochondrial Ca2+. However, this is very
unlikely since substrate availability governs only the path-
ways used to generate ATP, while workload or demand
is the principal determinant of respiration [12,28]. In
unloaded myocytes paced at a constant frequency, it is
expected that the workload is constant; therefore, it is un-
likely that acetate-induced changes in respiration underlie
the increase in mitochondrial Ca2+ uptake. Rather, we
consider the possibility that mitochondrial uptake of the
acetate anion is electrically balanced by the uptake of Ca2+
in line with the conclusion of others based on experiments
with isolated mitochondria [13-15].
Short chain fatty acids like acetate and butyrate may also
cause changes in intracellular pH with effects on contrac-
tion and SR Ca2+ content [29,30]. The current data do not
preclude a role for cytoplasm acidification in the effect of
acetate on myocyte contraction. However, the observa-
tions that acetate increases mitochondrial Ca2+ and that
pretreatment of cells with Ru-360 markedly attenuates the
effects of acetate argues that an acute change in mitochon-
drial Ca2+ uptake, rather than cytoplasmic acidification, is
the predominant mechanism underlying the effects of
acetate on contraction. Moreover, it is tempting to predict
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ate, or pyruvate) may cause similar changes.
Mitochondrial Ca2+ uptake and cardiovascular disease
In the heart, mitochondrial Ca2+ uptake has been proposed
as an important player in regulating cardiac energetics, re-
active oxygen species generation and supply–demand
matching [31,32]; however, mitochondrial Ca2+ overload is
also associated with the activation of cell death pathways
[33]. Thus a balance in mitochondrial Ca2+ loading is
required in order to achieve proper regulation of me-
tabolism, but avoid overloading and cell death. In
ischemia-reperfusion experiments, excessive Ca2+ uptake
is associated with a poor outcome, and treatment with
Ru-360 to inhibit mitochondrial Ca2+ uptake is beneficial
[34]. Acetate in this setting would be predicted to have no
effect or be detrimental, and this has been shown to be
the case [3,35-37]. Conversely, the failing heart has been
shown to have reduced mitochondrial Ca2+ resulting from
increases in cytosolic Na+ concentrations and increased
mitochondrial sodium-calcium exchange activity and
blocking mitochondrial Ca2+ export (i.e. enhancing mito-
chondrial Ca2+) is beneficial [38]. The data in the present
study suggest that elevating circulating acetate might
be an alternative strategy to accomplish this goal, al-
though it should be noted that the study presented here
was focused on the transient and not steady state conse-
quences of acetate.
Conclusions
In summary, we have shown that acetate causes an acute
but transient reduction in contractile function in isolated
cardiac myocytes. Mechanistically, the transient nega-
tive inotropic effect appears to result from an acetate-
dependent increase in mitochondrial Ca2+ uptake. This
finding is consistent with the results of Lehninger and
others using isolated liver and heart mitochondria, where
it has been shown that acetate causes an increase in mito-
chondrial Ca2+ uptake and osmotic swelling [13-15]. Here
we show that this effect appears to extend into intact, hy-
draulically unloaded cardiomyocytes, possibly suggesting a
novel way to modulate mitochondrial Ca2+ homeostasis in
the intact heart in vivo.Competing interests
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